19 episodios

Interviews and discussion from the 2016 WIN Symposium in Paris, 27th - 28th Jun 2016.

WIN 2016 ecancer

    • Medicina

Interviews and discussion from the 2016 WIN Symposium in Paris, 27th - 28th Jun 2016.

    • video
    Serum miRNAs as diagnostic tools in GI malignancies - Dr Ajay Goel

    Serum miRNAs as diagnostic tools in GI malignancies - Dr Ajay Goel

    Dr Goel speaks with ecancertv at WIN 2016 about micro RNAs (miRNAs), and their clinical use as prognostic or diagnostic markers for cancer diagnoses.

    He reports that RNA fragments isolated from a wide array of sample types can, with thorough assaying, lead to early diagnosis in patients and thus to more effective treatment, especially for those with GI malignancies.

    Dr Goel discusses how tumour heterogeneity can be monitored and treatments adjusted accordingly, based on miRNA sampling.

    • 3 min
    • video
    Precision cancer medicine in Korea - Dr Chang-Sik Yu

    Precision cancer medicine in Korea - Dr Chang-Sik Yu

    Dr Yu speaks with ecancertv at WIN 2016 about regulatory issues and development of precision cancer medicine in Korea.

    With ASAN Medical Centre being appointed the first Korean next generation sequencing-based clinical testing based laboratory system, Dr Yu considers other obstacles and opportunities in genomics being discussed at WIN.

    • 3 min
    • video
    Liquid biopsies to track clonal evolution and resistance in mCRC - Dr Alberto Bardelli

    Liquid biopsies to track clonal evolution and resistance in mCRC - Dr Alberto Bardelli

    Dr Bardelli meets with ecancertv at WIN 2016 to discuss the impact of liquid biopsy sampling on colorectal cancer treatment selection.

    By tracking the clonal evolution of tumours, he reports successes of genomic targeting for patients with HER2, TRK and ALK mutations, among others, and how samples can closely predict patient response, resistance and relapse.

    Dr Bardelli considers the evolutionary niche of cancer, and patient wellbeing outcomes as a result of liquid biopsy compared to solid tissue sampling.

    • 4 min
    • video
    Models and critical preclinical data shaping personal therapy - Prof Brian Leyland-Jones

    Models and critical preclinical data shaping personal therapy - Prof Brian Leyland-Jones

    Prof Leyland-Jones speaks with ecancer at WIN 2016 about the changing field of personalised medicine, from combination therapies to increasing availability of sequencing.

    He describes the need for investment in screening and upstream healthcare, as time and money spent in preventing cancer can have far-reaching impacts compared to reactive healthcare upon diagnosis.

    With proteomic, genomic and screening procedures becoming cheaper and more widely available, Prof Jones addresses how personalised therapy is becoming an affordable reality, with specific examples from other speakers at WIN 2016.

    • 5 min
    • video
    Affordable next generation sequencing to support decision making - Dr Elaine Mardis

    Affordable next generation sequencing to support decision making - Dr Elaine Mardis

    Dr Mardis speaks with ecancer at WIN 2016 about widening access to next-generation sequencing as part of clinical practice.

    She discusses barriers to accessing sequencing data, such as different models of insurance and reimbursement across the world, private companies which offer sequencing services, and determining actionable information from sequencing data.

    She highlights the value of open-source collaboration among oncologists to share and maximise the usefulness of genomic data, and anticipates its wider use alongside other new technologies.

    • 5 min
    • video
    New targets in personalised therapy for patients with lung cancer - Prof Bruce Johnson

    New targets in personalised therapy for patients with lung cancer - Prof Bruce Johnson

    Prof Johnson speaks with ecancertv at WIN 2016 about the impact of precision medicine on the diagnoses, management and treatment of lung cancer.

    From the first inclusion of EGFR in patient profiling to ALK and ABL targeting by modern therapies, Prof Johnson reports on increasing availability and specificity of personalised treatment.

    He also considers the impact of patient involvement and advocacy, especially in providing biopsy samples which inform future drug design.

    • 8 min

Top podcasts de Medicina

Más de ecancer